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Abstract Exendin-4, a peptide analogue of gluca-
gon-like peptide-1 (GLP-1), has been developed for
treatment of type 2 diabetes. Herein, the secretive
exendin-4 fusion protein, expressed by methanol
induction in Pichia pastoris system, was puriﬁed to
homogeneity by chromatography followed by entero-
kinase cleavage of the fusion protein and subsequent
puriﬁcation of the recombinant exendin-4. Purity of
the recombinant exendin-4 was 95.6%. Bioactivity
assay revealed that it had glucose-lowering and
insulin-releasing action in vivo.
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Introduction
Exendin-4 is a 39 amino acid peptide (53% structural
homology to GLP-1) and was ﬁrst isolated from the
salivary secretions of Gila monster lizard (Heloderma
suspectum)( E n ge t a l .1992). It shares many of the
glucoregulatory actions with GLP-1 (Buse et al. 2004;
Kendall et al. 2005) and has aroused great attention for its
potential for the treatment of diabetes. Clinical and non-
clinical studies have shown that exendin-4 has several
beneﬁcial anti-diabetic actions that include glucose-
dependent enhancement of insulin secretion, glucose-
dependent suppression of inappropriately high glucagon
secretion, slowing of gastric emptying, reduction of food
intake and body weight, and an increase in b-cell mass
(Buse et al. 2004; Edwards et al. 2001; Kendall et al.
2005; Kolterman et al. 2003;X ua n dK a n e t o2006).
For many years exendin-4 has been synthesized
chemically at a high price and is thus unsuitable for
mass production. It therefore needs to be produced in
quantity by genetic recombinant technology. Exendin-4
has been successfully expressed in E. coli system and it
proved having glucose-lowering action in vivo (Yi et al.
2006; Yin et al. 2005). However, no successful
expression in other expression systems has been
reported until now. For large-scale production, our
laboratory recently constructed a recombinant Pichia
pastoris that can produce exendin-4 constitutively and
secrete it into the broth (Zhuang et al. 2007). In this
study, the puriﬁcation and bioactivity of recombinant
exendin-4 expressed in P. pastoris are reported.
Materials and methods
Microorganism and expression of exendin-4
fusion protein
Pichia pastoris GS115 was transformed with plasmid
pPIC9 containing the gene encoding exendin-4,
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sion No. AAB22006). The details of the vector
construction and transformation were described else-
where (Zhuang et al. 2007). Recipes and
fermentation procedures were all followed by the
supplier’s protocol and were described brieﬂy as
follows. Fermentation of the pPIC9/exendin-4 trans-
formant of was carried out using a 30 l fermentor.
After 48 h of growth at 28C, the transformant
P. pastoris was induced by methanol for 72 h. The
culture was centrifuged at 5,000g for 15 min to
collect the supernatant which was used as the source
of recombinant protein.
Puriﬁcation of fusion protein
For the puriﬁcation of exendin-4, the total protein in
the supernatant was ﬁrst concentrated by ultraﬁltra-
tion using a 10 kDa molecular mass cutoff
membrane. The fusion protein was subsequently
puriﬁed by ion-exchange chromatography, hydropho-
bic interaction chromatography (HIC) and size-
exclusion chromatography. The void volume and
eluted fractions from the three chromatographic
columns were monitored at 280 nm. Fractions were
collected and subjected to SDS-PAGE analysis. The
puriﬁcation steps were shown in Table 1.
Cleavage of the fusion protein by enterokinase
After desalting, the fusion protein was incubated with
enterokinase (1 U/1 mg fusion protein) at 37C for
8 h to obtain the recombinant exendin-4. The reaction
mixture was analyzed by Tricine SDS-PAGE. The
recombinant exendin-4 was puriﬁed by Sepharose
G-25 column and its purity was assayed by HPLC.
SDS-PAGE, Tricine SDS-PAGE, immunoblotting
and protein determination
Proteins were analyzed by SDS-PAGE under reduc-
ing conditions using 12% (v/v) gels. Tricine SDS-
PAGE was carried out with the supplier’s protocol
(Amersham Bioscience). The separated proteins were
stained with Coomassie Brilliant Blue R-250 or
electroblotted to nitrocellulose membrane for western
blotting. After blocking with 3% (v/v) non-fat milk in
0.05% Tween/PBS (PBST), the membrane was
washed 3 times with PBST for 10 min and incubated
further with a 1:2,000 dilution of polyclonal rat anti
exendin-4 antibody for 1 h, followed by washing as
was described above. The membrane was incubated
with a 1:1,000 dilution of HRP-conjugated goat anti-
rat IgG as the second antibody, washed with the same
procedure as above and revealed with DAB substrate
(Sigma). Protein concentration was determined by the
method of Bradford using bovine serum albumin as a
standard.
Biological activity assay
The effects of recombinant protein exendin-4 on
plasma glucose concentration and insulin levels were
examined using 8 week-old male Wistar rats. Ani-
mals were housed six per cage (three repetition) at
24C environmental conditions with free access to
food and water. They were allowed one week to adapt
to their environment before the experiment. Food was
withdrawn for 24 h before intraperitoneal injection of
glucose (20 mM/kg body weight) alone or in com-
bination with exendin-4 (10 nmol/kg body wt). Test
solutions were administered in a ﬁnal volume of
1 ml/kg body weight (O’Harte et al. 2000). Blood
samples were collected at 15, 30 and 60 min after the
injection from the eye socket with capillary into
chilled heparin Eppendorf tubes. Blood samples were
centrifuged and plasma samples were stored at
-20C before determination.
Plasma glucose and insulin level were assayed
respectively by a glucose assay kit and insulin
enzyme linked immunosorbent assay kit (Dingguo,
Beijing). Results were expressed as mean ± SE and
were analyzed by one-way analysis of variance
(ANOVA) by SPSS 11.0 software. Differences were
considered signiﬁcant at P\0.05.
Results
Expression and detection
The results of expression and detection exendin-4
fusion protein are given in Fig. 1.
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recombinant exendin-4 by enterokinase cleave
Puriﬁcation of the fusion protein and production of
the recombinant exendin-4 by enterokinase cleavage
are given in Table 1 and further details were shown
in Fig. 2.
Bioactivity of exendin-4 in vivo
Figure 3 showed the results of bioactivity of exendin-
4 in vivo. Compared with the control group, plasma
glucose concentration in GLP-1 group was signiﬁ-
cantly reduced (P\0.05) at 30 min, and the same
phenomenon was observed after 60 min in exendin-4
group (Fig. 3a). There was no difference between the
glucose-lowering capabilities of treatment group and
control group before 15 min. The capabilities of
stimulating insulin secretion showed signiﬁcant
response to GLP-1 and exendin-4 supplementation.
The maximal increase in insulin in rat treated with
GLP-1 was 2 times higher than the control group
before 30 min. The plasma insulin concentration of
exendin-4 treated group was also signiﬁcantly raised
(P\0.05) at 30 min compared with the control
group and the capabilities of stimulating insulin
secretion by exendin-4 could keep to 60 min
(Fig. 3b).
Discussion
For many years, the production of exendin-4 was by
chemical synthesis which necessitated a high cost.
Recently, bioengineering methods of producing exen-
din-4 have appeared. Yi et al (2006) and Yin et al
(2005) cloned the exendin-4 gene and obtained stable
expression in E. coli.H o w e v e r ,t h eE. coli-expressed
exendin-4 existed initially in inclusion bodies and
bioactivity was realized only after renaturation, which
made the puriﬁcation process complicated and led to a
low yield. Furthermore, clinical application of bacte-
rially produced products may be affected by the
possible presence of endotoxins that sometimes con-
taminate protein preparations expressed by E. coli.W e
have several reasons to select P. pastoris as an
alternative recombinant expression host for exendin-4
synthesis. P. pastoris has the advantages of large
production, genetically stable expression strains, the
potential to secrete recombinant proteins into culture
medium, and simple inexpensive culture conditions
(Patrick et al. 2005). In this study, the highest
expression level of fusion protein exendin-4 was
estimated at about 580 mg/l culture, which was higher
than E. coli system. In addition, Pichia pastoris-
synthesized recombinant exendin-4 was effectively
puriﬁed from the culture medium through four chro-
matograph steps in this study. The whole puriﬁcation
process was simple and easy. These properties make
Table 1 Summary of exendin-4 puriﬁcation
Puriﬁcation step Total protein (mg) Protein of interest
a (mg) Recovery (%)
Fusion exendin-4 Broth supernatant 1,640 580 100
DEAE A-25 1,200 390 67
Phenyl FF 760 285 49
G-75 410 214 37
Recombinant exendin-4 G-25 214 26 4.5
The concentrated broth supernatant was dialyzed with buffer A (20 mM Tris/HCl, pH 6.0, 1 mM EDTA) and was applied to a DEAE
Sephadex A-25 (DEAE A-25) (100 ml bed volume) equilibrated with buffer A beforehand, at 1 ml/min. The column was washed
with 300 ml buffer A and then eluted with a linear gradient of 0 to 1 M NaCl in buffer A. The eluted fractions containing exendin-4
were pooled and dialyzed. The desalted protein was mixed with ammonium sulfate at 1 M and applied onto a phenyl-Sepharose Fast
Flow (Phenyl FF) column (50 ml bed volume) pre-equilibrated with buffer B [20 mM Tris/HCl, pH 6.0, 1 M (NH4)2SO4,1m M
EGTA] at 1 ml/min, the column was washed with 150 ml buffer B and eluted with a linear (NH4)2SO4 gradient from 1 to 0 M in
buffer B. The peak with exendin-4 was concentrated and dialyzed with buffer C (50 mM PBS, pH 6.0, 10% (v/v) glycerol). The last
step of puriﬁcation was through a Sephadex G-75 column (1 9 50 cm) pre-equilibrated with buffer C at 0.5 ml/ min. For
recombinant protein puriﬁcation, the pool of fractions containing puriﬁed fusion protein from the three columns was dialyzed in
20 mM Tris/HCl (pH 6.0)
a The amount of protein of interest was determined by quantifying the amount in each gel lane by densitometry (Totallab V1.11
software)
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of exendin-4.
Tothebestofourknowledge,thisistheﬁrststudyto
directly investigate the effects of recombinant exen-
din-4expressedinP.pastorisonglucose-loweringand
Fig. 1 Expression and detection of exendin-4 fusion protein.
(a) SDS-PAGE analysis of the expression level of fusion
exendin-4 at different time in hours. After 56 h, the amount of
the fusion protein expression reached the maximum (580 mg/
l). Fifteen micro liter of supernatant were applied to a 12% gel
and then stained with R-250. Lane 1, control transformant
GS155/pPIC9 after 72 h culture; Lanes 2–10, recombinant
GS115/pPIC9/exendin-4 after 8, 16, 24, 32, 40, 48, 56, 64 and
72 h of culture; The position of the target proteins induced by
methanol is indicated by arrow. (b) Western blotting analysis
of expressed protein in P. pastoris. Lanes 1–8 expressed
protein of recombinant GS115/pPIC9/exendin-4 after 0, 8, 16,
24, 32, 40, 48 and 56 h, lane 9 expressed protein of control
transformant GS115/pPIC9
Fig. 2 (a) Puriﬁcation of the exendin-4 fusion protein by three
chromatography steps. Lane 1, broth supernatant; lane 2,
DEAE A-25; lane 3, Phenyl FF; lane 4, G-75; M is protein
marker (KDa). (b) Puriﬁcation of the recombinant protein
exendin-4 by a G-25 column. Lane 1, reaction mixture of
fusion protein cleaved by enterokinlase. Recombinant exendin-
4 (4.3 kDa) is marked by arrow; lane 2, the non-target protein
eluted from the G-25 column; lane 3, puriﬁed recombinant
peptide exendin-4 from G-25 column. (c). The purity analyzed
by HPLC was 95.6% which was performed on a 250 mm
9 4.6 mm C5 column. The column was eluted with the linear
gradient of acetonitrile (90–0%) in 0.1% triﬂuoroacetic acid for
35 min at 0.5 ml/min. The target peak was at 18.3 min
654 Biotechnol Lett (2008) 30:651–656
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ability of native peptide GLP-1 to reduce plasma
glucose to a certain level was at 30 min, while the
activity of exendin-4 appeared at 60 min (Fig. 3a). It
indicated that the exendin-4 has a longer duration of
action and a greater potency than GLP-1 (Fig. 3a).
Insulin is one of the most important hormonal immune
responsesand is linked to glucose-lowering responses.
Although reports on inﬂuence of administration of
exenatides on insulin activity are not very consistent,
this function can be enhanced by injection adminis-
tration of exendin-4 or its analogue (Gedulin et al.
2007; Kolterman et al. 2003; Nielsen et al. 2004;X u
and Kaneto 2006). The present study observed similar
phenomenon. Furthermore, we observed that the
capabilities of stimulating insulin secretion by GLP-1
was maintained up to 30 min, while exendin-4 was up
to 60 min (Fig. 3b). Thus the half-life of exendin-4 in
plasma is longer than GLP-1. There are two main
reasons for this. One reason is that the exendin-4 lacks
many of the neutral endopeptidase substrate sites
present in GLP-1 and has a nine-AA sequence at the
C-terminus absent from GLP-1 (Hupe et al. 1995).
Another one is that the N-terminal sequence (His:
Gly:Glu) of exendin-4 is not recognized by
dipeptidylpeptidase (IV) (DPP (IV)), which rapidly
cleaves the His:Ala:Glu sequence found on the
N-terminus of GLP-1 (O’Harte et al. 2000). In our
opinion, we should not rule out the presumption that
the exendin-4 (4.3 kDa) has higher molecular weight
than GLP-1 (3.1 KDa), which can reduce the glomer-
ular ﬁltration in vivo.
It is important to note that in the three independent
experiments, the recombinant exendin-4 did not have
obvious effects on one or two rats of the six. It was
probably because of individual differences. The
results of the three independent experiments were
comparable. According to the research, the recombi-
nant exendin-4 may also have effects at smaller doses
but remains to be proved.
In summary, we have achieved high-level secre-
tion of biologically active exendin-4 in P. pastoris.
The result of the study indicated that although the
heterogeneity-expressed exendin-4 in P. pastoris was
slightly different from native GLP-1 in biological
value, it still maintained good bioactivity. High purity
and stability of the recombinant peptide of exendin-4
after puriﬁcation makes it possible to be a therapeu-
tical drug in the future. In the next step, we will focus
on structure analysis and evaluation of the safety of
exendin-4.
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Fig. 3 Biological activity assay of exendin-4 in rats. The
capabilities of glucose-lowering (a) and insulin-releasing (b)
after intraperitoneal glucose alone (20 mM/kg) (control group),
or glucose in combination with either exendin-4 (trial group) or
GLP-1 (positive group) (10 nmol/kg). The time of injection is
indicated by the arrow (0 min). Values are mean ± SE
(n = 6). Asterisk denotes statistically signiﬁcant differences
(P\0.05) between control and trial (or positive) groups by
one-way ANOVA
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